Anti-CD20 therapies in multiple sclerosis (MS) have become central to management of the disease since their FDA approval in 2017. As their role in MS management continues to grow, it is also increasingly important to know how such drugs can be better administered using current knowledge of how B cells repopulate after their depletion. To this end, individualizing therapy needs to be prioritized since a timed-dosing interval is perhaps not required based on evidence and it certainly unwelcome from a financial perspective.